European Healthtech startup funding raised during H2 2014.
In H2 2014, 62 European Healthtech companies raised a combined €543M across 64 funding rounds, up 65.2% versus H2 2013. UK led by capital raised, and Life Sciences Partners was the most active investor. Data as of 7 Aug 2026.
2 exits · €16M disclosed.
| Company | Stage | Date | Amount |
|---|---|---|---|
| Adaptimmune | Series A | Sep 2014 | €79M |
| Biocartis | Series D+ | Sep 2014 | €65M |
| Cell Medica | Series B | Nov 2014 | €64M |
| Ascendis Pharma | Series C | Dec 2014 |
| GenKyoTex |
| Acquisition |
| Nov 2014 |
| €16M |
| €48M |
| Quanta Fluid Solutions | Series B | Nov 2014 | €34M |
| Xeltis | Series B | Dec 2014 | €27M |
| Gamida Cell | Growth/Late | Aug 2014 | €26M |
| MagForce | Other | Aug 2014 | €14M |
| AM-Pharma | Series D+ | Sep 2014 | €12M |
| Anergis | Series B | Dec 2014 | €12M |
| NeuroDerm | Growth/Late | Aug 2014 | €12M |
| GI View | Other | Dec 2014 | €10M |
| Sophia Genetics | Series B | Jul 2014 | €10M |
| Check-Cap | Other | Oct 2014 | €9.5M |
| Rigontec | Series A | Oct 2014 | €9.4M |
